Table 1 Clinical characteristics of autosomal-dominant STAT5B-deficient index patients and comparison to previously reported autosomal-recessive STAT5B cases

From: Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation

 

Proband 1 [p.Gln177Pro]

Proband 2 [p.Ala478Val]

Proband 3 [p.Gln474Arg]

Published AR cases {n}

Sex

Male

Male

Female

f/m = 7/3 {10}

Age (years)

14.5

1.8

12.8a

1.9–18.0 {10}

Birth data

    

Gestational age (weeks)

36

39

39

Preterm: 6/8 {8}

Birth weight (g) [SDS]

2500 [−0.9]

3460 [0.1]

3317 [0.2]

[−2.4 to 3.0]b {6}

Birth length (cm) [SDS]

45 [−1.7]

nd

48 [−0.2]

[−2.4 to 2.3]b {5}

Auxological features

    

Weight (kg) [SDS]

28.0 [−4.5]

9.5 [−2.3]

22.8 [−4.7]

[−6.7 to −3.6] {4}

Height (cm) [SDS]

131.5 [−5.3]

76.8 [−2.9]

123.8 [−4.5]

[−9.9 to −4.3] {10}

Target height (SDS)

−0.74

−0.83

−1.01

−1.98 to −0.11 {8}

Head circumference (SDS)

−0.53

−1.70

−3.73

−1.40, −2.86 {2}

Bone age (years)

9.6

nd

8.8

Delayed: 7/7 {7}

Puberty

Delayed

na

Delayed

Delayed: 6/7 {7}

Endocrine features

    

GH, basal (ng ml−1)

0.4

3.2

2.0

0.1–17.6 {10}

GH, stimulated (ng ml−1)

16.2

17.3

4.0

6.6–53.8 {7}

IGF1 (ng ml−1) [SDS/reference range]

56 [76–499]

<25 [51–303]

208 [−1.5]

<normal: 10/10 {10}

IGFBP3 (mg l−1) [SDS/reference range]

2.33c [−1.7]

1.29 [0.8–3.9]

3.80 [3.9–9.4]

<normal: 10/10 {10}

IGFALS [reference range]

418 p mol l−1 c [986–1678]

nd

13 mg l−1 [5.6–16.0]

<normal: 6/6 {6}

Prolactin (mU l−1) [reference range]

291c [86–324]

553 [163–1039]

621d [<383]

>normal: 6/7 {7}

Immunological and pulmonary phenotype

    

IgE (kU l−1) [reference range]

156/340e [<200/<114]

118 [<52]

127 [<629]

>normal: 4/7 {5}

Hemorrhagic Varicella

No

No

No

5/5 {5}

Chronic pulmonary disease

Recurrent infections

No

No

8/10 {10}

Lung fibrosis

nd

nd

No

6/7 {7}

Lymphocytic interstitial pneumonia (LIP)

nd

nd

No

7/8 {8}f

Eczema/skin pathology

Yes

Yes

No

8/8 {8}

Otherwise disturbed immunological profiles

No

No

No

5/7 {7}

Autoimmune disease

No

No

Thyroiditis; celiac disease

6/10 {10}f

  1. nd not determined, na not applicable. Standard deviation scores (SDS) and reference ranges are shown in brackets with reference ranges in italics
  2. a Patient on GH treatment for 3 months
  3. b Six of eight patients born AGA (appropriate for gestational age)
  4. c Determined at age 16.5 years during rhIGF treatment
  5. d Measured at 15.3 years while on rhIGF1 for 4 months
  6. e Measured at two occasions
  7. f Diagnosis confirmed or suspected